Redhill Biopharma Signed A Collaborative Research Agreement With Duke University School Of Medicine Outlining Plans For Multiple In Vivo Studies, To Test Opaganib As A Potential Medical Countermeasure To Treat Phosgene Inhalation Injury
Portfolio Pulse from Benzinga Newsdesk
Redhill Biopharma has entered into a collaborative research agreement with Duke University School of Medicine to conduct in vivo studies on Opaganib for treating phosgene inhalation injury. Redhill will supply the drug and provide analytical support.
October 22, 2024 | 11:13 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Redhill Biopharma has signed a research agreement with Duke University to test Opaganib for phosgene inhalation injury, potentially expanding its drug applications.
The partnership with Duke University to test Opaganib in new applications could lead to expanded uses for the drug, potentially increasing its market value and Redhill's stock price. The collaboration indicates a strategic move to diversify and strengthen Redhill's product pipeline.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 90